Metformin, a medication that has been the standard treatment for Type 2 diabetes for more than six decades, is once again attracting global attention. This time, the focus is not on controlling blood sugar but on its potential to slow biological ageing and delay age-related diseases.
Scientists are exploring whether the inexpensive diabetes drug could help people live healthier for longer. The growing excitement follows the launch of the Targeting Aging with Metformin (TAME) trial in the United States, the first large-scale clinical study designed specifically to determine whether a medicine can target ageing itself rather than a single disease.
However, doctors caution that despite promising laboratory and observational studies, there is still no conclusive evidence that healthy people should take metformin for longevity.
Why researchers believe metformin could slow ageing
Metformin has long been prescribed as the first-line medication for Type 2 diabetes because it improves insulin sensitivity and helps regulate blood glucose levels.
Over the past decade, researchers noticed something unexpected. Several observational studies suggested that diabetic patients taking metformin appeared to experience lower rates of certain age-related illnesses and, in some cases, even lived longer than individuals without diabetes.
These findings encouraged scientists to investigate whether the drug influences biological pathways linked to ageing.
Experts believe metformin may reduce chronic inflammation, improve insulin resistance and activate cellular repair mechanisms associated with healthier ageing. Laboratory studies have shown that the drug activates AMPK, often described as the body's cellular energy sensor, while reducing insulin and IGF-1 signalling pathways that have been linked to ageing in animal research.
What is the TAME trial?
The Targeting Aging with Metformin (TAME) trial is considered one of the most ambitious longevity studies ever proposed.
Unlike traditional medical trials that focus on treating a single disease, TAME aims to determine whether metformin can delay the onset of multiple age-related conditions simultaneously, including:
-
Cardiovascular disease
-
Dementia
-
Cancer
-
Other chronic illnesses associated with ageing
Instead of measuring lifespan alone, researchers will evaluate whether participants remain healthier for longer by delaying disease development.
The US Food and Drug Administration (FDA) has approved the study design, making it the first major trial to formally investigate ageing as a treatable biological process.
Why the trial has faced delays
Despite widespread scientific interest, the TAME trial has struggled to secure funding.
Since metformin is an inexpensive generic drug, pharmaceutical companies have little financial incentive to invest the estimated $45–70 million required to complete the research.
Importantly, FDA approval of the study design does not mean the agency has approved metformin as an anti-ageing medicine.
Earlier hopes beyond diabetes
Metformin has previously generated excitement for other possible health benefits.
Observational studies suggested the medicine might reduce the risk of cancers affecting the liver, pancreas and colon. However, larger randomised clinical trials failed to consistently confirm these benefits.
Researchers say this highlights why promising observational evidence must always be validated through rigorous clinical trials before changing medical practice.
Doctors urge caution
Medical experts say metformin remains a valuable medicine for people who require it for approved medical conditions such as Type 2 diabetes and, in some cases, polycystic ovary syndrome (PCOS).
However, they strongly advise healthy individuals not to start taking the drug solely for longevity.
Current research has not established that metformin increases lifespan in healthy adults. Instead, scientists are investigating whether it can extend the number of healthy years people live by delaying chronic diseases.
Doctors also point out that metformin is a prescription medicine and is associated with potential side effects, including:
-
Digestive discomfort
-
Nausea and diarrhoea
-
Vitamin B12 deficiency with long-term use
-
Rare but serious lactic acidosis in susceptible patients
Because of these risks, experts discourage self-medication based on social media trends or headlines.
Healthy ageing still depends on lifestyle
While the scientific community awaits the results of the TAME trial, doctors continue to recommend proven lifestyle measures for healthy ageing.
These include maintaining a balanced diet, exercising regularly, getting adequate sleep, avoiding tobacco, and managing chronic conditions such as diabetes, obesity and hypertension.
Researchers believe the TAME study could reshape the future of ageing medicine if it successfully demonstrates that a single medication can delay multiple diseases associated with growing older. Until then, metformin's role as a longevity drug remains promising—but unproven.
Frequently Asked Questions (FAQs)
Is metformin approved as an anti-ageing drug?
No. Metformin is approved for treating Type 2 diabetes and certain other medical conditions, but it has not been approved as an anti-ageing medication.
What is the TAME trial?
The Targeting Aging with Metformin (TAME) trial is a landmark US clinical study designed to determine whether metformin can delay age-related diseases and promote healthier ageing.
Should healthy people take metformin for longevity?
Doctors do not recommend metformin for healthy individuals outside clinical trials because there is currently insufficient evidence to prove its anti-ageing benefits.
What are metformin's common side effects?
Common side effects include stomach upset, diarrhoea, nausea and long-term vitamin B12 deficiency. Rarely, it may cause lactic acidosis in susceptible individuals.
